First‐in‐human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males

AIMS: The aim of the present study was to investigate the safety, tolerability, dose proportionality and relative bioavailability of tablet and oral solution formulations of BI 409306 in healthy male subjects, and to compare the safety and pharmacokinetics in subjects who were extensive metabolizers...

Descripción completa

Detalles Bibliográficos
Autores principales: Moschetti, Viktoria, Boland, Katja, Feifel, Ulrich, Hoch, Anja, Zimdahl‐Gelling, Heike, Sand, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061793/
https://www.ncbi.nlm.nih.gov/pubmed/27378314
http://dx.doi.org/10.1111/bcp.13060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061793/
https://www.ncbi.nlm.nih.gov/pubmed/27378314
http://dx.doi.org/10.1111/bcp.13060

Ejemplares similares